EVEROCAN, PHARMACOR EVEROLIMUS (Pharmacor Pty Ltd)
Product name
EVEROCAN, PHARMACOR EVEROLIMUS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
146 (255 working days)
Active ingredients
everolimus
Registration type
New generic medicine
Indication
EVEROCAN, PHARMACOR EVEROLIMUS (tablet) is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 Special warnings and precautions for use).